Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Rhône-Poulenc

From Wikipedia, the free encyclopedia
This articleneeds additional citations forverification. Please helpimprove this article byadding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Rhône-Poulenc" – news ·newspapers ·books ·scholar ·JSTOR
(August 2022) (Learn how and when to remove this message)
Defunct French Agriculture Company
Rhône-Poulenc
Rhône-Poulenc
Company typemerged withHoechst AG
IndustryChemicals
Founded1928; 97 years ago (1928)
FounderÉtienne Poulenc
ProductsChemicals and pharmaceuticals

Rhône-Poulenc (French pronunciation:[ʁonpulɛ̃k]) was a French chemical and pharmaceutical company founded in 1928. In 1999, it merged withHoechst AG to formAventis. As of 2015, the pharmaceutical operations of Rhône-Poulenc are part ofSanofi and the chemicals divisions are part ofSolvay group andBayer Crop Science.

History

[edit]
Founder's stock certificate of the Société des Usines Chimiques Rhône-Poulenc for 100 francs, issued on 5 September 1928 in Paris, with the signature of Hippolyte-Eugène Boyer as Chairman of the Supervisory Board
Founder's stock certificate of the Société des Usines Chimiques Rhône-Poulenc for 100 francs, issued on 5 September 1928 in Paris, with the signature of Hippolyte-Eugène Boyer[1] as Chairman of the Supervisory Board

The company was founded in 1928 through the merger ofSociété des usines chimiques du Rhône (Society of Rhône Chemical Factories) from Lyon andPoulenc Frères (Poulenc Brothers) from Paris founded by Étienne Poulenc, a 19th-century Parisian apothecary and brought to prominence by his second and third sons Émile, father of composerFrancis Poulenc, and Camille Poulenc (1864–1942). Établissements Poulenc Frères had purchased May & Baker in 1922, the latter continuing to trade under its original name until 1990.

In 1950, the company synthesizedchlorpromazine which it sold to Smith, Kline & French (today part ofGlaxoSmithKline) who marketed the drug as Thorazine.[2] In 1986, Rhône-Poulenc acquired the German pharmaceuticalA. Natterman & Cie GmbH.[3] In 1990, it merged with the pharmaceutical company Rorer to form Rhône-Poulenc Rorer.[4] In January 1999, Rhône-Poulenc merged withHoechst AG to form Aventis. In 2004, Aventis went on to merge with Sanofi-Synthélabo forming Sanofi-Aventis, the third-largest pharmaceutical company in the world. In 2011, Sanofi-Aventis decided to drop the Aventis suffix and change its name toSanofi.

The company was bought by Établissements Poulenc Frères (later to become Société des Usines Chimiques Rhône-Poulenc) in 1922, and subsequently moved to Dagenham, Essex, although it continued to trade under the May & Baker name.

In 1997, its chemicals division was spun off into a separate company namedRhodia and was later acquired by theSolvay group in 2011. The agricultural chemicals division of Rhône-Poulenc, known as Aventis CropScience after the merger with Hoechst, was sold to the German chemical and pharmaceutical companyBayer in 2002.

In 1997 Rhône-Poulenc came to play a central part in what is claimed to be the worst environmental accident in Sweden's history. Rhône-Poulenc suppliedRhoca-Gil for the building of theHallandsås tunnel. The chemical leaked into the artesian water, causing great damage to cattle, surrounding nature and workers at the construction site.Rhône-Poulenc was criticised for not pointing out the risks of using the sealant, which containedacrylamide and is considered to be carcinogenic. Criminal charges were brought against the company and In June 2001, the managing director of the former Rhône-Poulenc Sweden was found guilty of breaching the Chemical Products Act, and was to pay 60day-fines at SEK650 for a total of SEK60,000.[5]

Rhône-Poulenc originally funded theRhône-Poulenc Prizes, now known as theRoyal Society Prizes for Science Books.

Literature

[edit]
  • Chauveau, Sophie. 1999. L'Invention pharmaceutique : la pharmacie française entre l'État et la société au XXe siècle. Le Plessis-Robinson: Sanofi-Synthélabo.

See also

[edit]

References

[edit]
  1. ^https://dfih.fr/persons/51031 | DFIH — Data for Financial History | Person: Hippolyte-Eugène Boyer
  2. ^Whitaker, Robert (2002).Mad in America. Perseus (Basic Books). p. 142.ISBN 978-0-465-02014-0.
  3. ^"Rhone-poulenc drug strategy includes "Eventual" U.S. Expansion".Pharma Intelligence. 1987-03-09. Retrieved2023-08-05.
  4. ^"Rhône Poulenc". Archived fromthe original on 2015-11-28. Retrieved2015-09-08.
  5. ^Mårald (2007), p. 111-117 -See also printed sources
Predecessors
CEOs
Main products
Cardiovascular
Thrombosis
Oncology
Diabetes
Central nervous system
Internal medicine
Subsidiaries
Chattem Inc.
Brands
Others
International
National
Other
Retrieved from "https://en.wikipedia.org/w/index.php?title=Rhône-Poulenc&oldid=1245170371"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp